Dr. de Min brings over 25 years’ experience in drug development in both big pharma and biotech. She will drive the advancement of Topas’ development programs, including lead clinical program TPM203 for treatment of pemphigus vulgaris and TPM502 for treatment of celiac disease.

Allecra Therapeutics and Advanz Pharma Sign Exclusive License and Supply Agreement for Allecra’s Antibiotic Cefepime/enmetazobactam in Europe
Allecra receives upfront, development and commercial milestone payments, in addition to double-digit royalties. Advanz gains commercial rights for cefepime/enmetazobactam in the European Union, the United Kingdom, Switzerland, and Norway
BioNTech and Crescendo Biologics Announce Global Collaboration to Develop Multi-specific Precision Immunotherapies
Collaboration leverages BioNTech’s proprietary multimodal immunotherapy expertise with Crescendo’s proprietary Humabody VH platform to develop precision immunotherapies, including mRNA-based antibodies and engineered cell therapies against targets selected by BioNTech. Crescendo will receive $40 million upfront, including a cash payment and an equity investment from BioNTech, as well as research funding, and will be eligible to receive development, regulatory and commercial milestone payments up to a total of more than $750 million, plus tiered royalties on global net sales.